A new remedy for Alzheimer's disease that acquires the approval of American experts

A new remedy for Alzheimer’s disease obtained the approval of an advisory committee, composed of American experts, who pave the way for issuing health authorities in the United States, a positive decision on the leave of the new drug use. 11 Independent experts collected at the request of the American Food and Drug Administration (FDA) to audit the clinical experience data that the Donnemab, reached by the Eli Lilly group, has proven effective in patients still in the early stage of the disease. Experts said in a second vote that the benefits of these medicines exceed the risks, and expert Sarah Doulan said there is a ‘great’ need for new medicine, although patients and doctors ‘will have to receive a lot of information’ about Eli Lilly to get a good follow -up. However, a number of experts have regretted the lack of data regarding some of the population categories within the clinical experience, especially with regard to African Americans, and the recommendation of the committee is not binding for “FDA”, but it is not rarely followed by authority. A new remedy for Alzheimer’s disease belongs to a new category of medicine against Alzheimer’s disease that patients and their families are attached to great hope, and Dunanimab is taken from the intravenous path, and works to destroy the plates formed by proteins in the brain of patients called “amiloid”. A clinical trial has shown that Donnimab slows down the development of this degenerative disease, but in return it causes serious side effects in some patients as it can lead to brain bleeding. In the spring, the US Food and Drug Administration in the spring decided to delay the expected license for the drug to further check the data and obtain the opinion of this expert committee. In May 2023, “FDA” was summarized by a similar property against Alzheimer’s filed on the market as “Leqembi”, manufactured by the Japanese drug group “Eisai”, in collaboration with the US “biogen” and forms its active component. The decisions regarding Alzheimer’s disease have become a strict investigation, as the controversy over the first means of this category is the ‘aduhelm of’ biogen ‘. Alzheimer’s has been stagnant for decades, and ‘Adohil’ was the first cure for the disease since 2003. Alzheimer’s disease is a nervary of disorders, character and the pathological features of Alzheimer’s the presence of amyloid Bita, and nerve fibroids consisting of a toxic protein. Protein can improve the brain’s ability to remove amyloid plates, which is the characteristic of Alzheimer’s disease.